Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Parasitic organism or component thereof or substance...
Patent
1978-08-22
1979-12-04
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Parasitic organism or component thereof or substance...
A61K 31415
Patent
active
041772822
ABSTRACT:
Several novel dextrotatory spiro-hydantoin compounds have been obtained by resolving the corresponding dl-compounds which are initially synthesized by first condensing the appropriate carbonyl ring compound, such as the corresponding 4-chromanone or thiochroman-4-one, as the case may be, with potassium cyanide and ammonium carbonate. The resulting optically-active hydantoin derivatives, such as d-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione and d-6'-fluoro-spiro-[imidazolidine-4,4'-thiochroman]-2,5-dione, are particularly useful in preventing or alleviating chronic diabetic complications.
REFERENCES:
patent: 2683718 (1954-07-01), Dornfeld et al.
Arnold et al., Chemical Abstracts, 1963, 58:3439-3440.
Boehme et al., Chemical Abstracts, 1974, 80:108305(u).
Karrer et al., Organic Chemistry, 2nd English ed., pp. 93-99, N.Y., Elsevier, 1946.
Goldberg Jerome D.
Pfizer Inc.
LandOfFree
Hydantoin therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydantoin therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydantoin therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-91900